HER2 in Colorectal Cancer

by Jason Wasserman MD PhD FRCPC
November 19, 2026


Print this article

HER2, also known as ERBB2, is a gene that drives cancer cell growth when it is overactive. HER2 is best known in breast and stomach cancer, but it is also found in a small number of colorectal cancers. Until recently, a HER2-positive result in colorectal cancer did not lead to a specific treatment. Now, two HER2-targeted treatments are approved by the US Food and Drug Administration (FDA) for HER2-positive colorectal cancer that has spread. A HER2 result can also help explain why a cancer is not responding to some other targeted drugs.

This article explains what a HER2 result means on a colorectal cancer report, how the test is done, and how the result shapes treatment decisions.

What HER2 is and what it does

HER2 is a gene that holds the instructions for a protein called the HER2 receptor. This protein sits on the cell surface and receives signals that tell the cell to grow and divide. A healthy cell has a small amount of HER2. In some colorectal cancers, the HER2 gene is amplified, meaning extra copies are present. The cell then makes far too much HER2 protein, which sends growth signals that never switch off.

These changes in colorectal cancer are somatic, meaning they develop in the cancer cells during a person’s lifetime and are not inherited. Less often, the HER2 gene carries a mutation, a small change in the gene’s code that can switch the HER2 protein on. Amplification and mutation are different changes, and they are found and treated differently.

How common is HER2-positive colorectal cancer?

HER2-positive results are found in about 3% to 5% of colorectal cancers. The rate is higher, about 5% to 8%, in cancers that do not have mutations in the KRAS and NRAS genes. HER2-positive colorectal cancers share a characteristic profile:

  • Left-sided location. About 95% of HER2-amplified colorectal cancers start on the left side of the colon or in the rectum. This contrasts with BRAF V600E mutations, which are more common on the right side.
  • RAS and BRAF wild-type. HER2 amplification rarely occurs together with KRAS, NRAS, or BRAF mutations. Wild-type means no mutation was found in those genes.
  • Resistance to anti-EGFR drugs. HER2 amplification is linked to a poor response to cetuximab and panitumumab, two drugs that block a related protein called EGFR.

Why is the test done?

HER2 testing in colorectal cancer is done for three main reasons:

  • To find out whether HER2-targeted drugs may help. Two HER2-targeted treatments are approved for HER2-positive colorectal cancer that cannot be removed with surgery or has spread. The NCCN Guidelines recommend HER2 testing for metastatic colorectal cancer, especially when no KRAS, NRAS, or BRAF mutation is found.
  • To help plan anti-EGFR treatment. Testing before anti-EGFR drugs are chosen gives the oncologist a fuller picture. A HER2-positive cancer may respond poorly to them even when RAS and BRAF are wild-type.
  • To add context to the outlook. Some studies link HER2-positive colorectal cancer to a less favorable outlook, while others do not. For now, the treatment implications of the result matter more than its effect on prognosis.

How the test is performed

HER2 testing in colorectal cancer is performed on tumor tissue from a biopsy or a surgically removed specimen. Three types of tests can be used: IHC, ISH, and NGS. Unlike breast and stomach cancer, colorectal cancer has no single scoring guideline that every laboratory follows.

Immunohistochemistry (IHC)

Immunohistochemistry (IHC) uses antibodies to stain the HER2 protein on a thin slice of tumor tissue. A pathologist examines the slide and judges how strong the staining is at the cell membrane. The score runs from 0 to 3+.

Laboratories use one of two main approaches to scoring:

  • Colorectal-specific rules. These were developed in a trial called HERACLES. A score of 3+ must be seen in more than half of the cancer cells. A score of 2+ in more than half of the cells needs ISH to decide the result.
  • Breast or gastric rules. These use a lower cut-off of 10% of the cancer cells, in the trial that led to the first colorectal approval, the breast and gastric rules gave the same final result in nearly every case.

Your report may name the scoring system used. If it does not, your pathologist or oncologist can tell you.

In situ hybridization (ISH or FISH)

In situ hybridization (ISH), including the fluorescent form called FISH, counts the copies of the HER2 gene in the cancer cells. It compares them with a control region on chromosome 17. A ratio of 2.0 or higher indicates gene amplification. ISH is usually done when the IHC score is 2+.

Next-generation sequencing (NGS) and liquid biopsy

Next-generation sequencing (NGS) reads many genes at once. In metastatic colorectal cancer, a single NGS test often checks KRAS, NRAS, BRAF, mismatch repair, and HER2 together. NGS can find extra copies of the HER2 gene, and it can also find HER2 mutations.

NGS plays a bigger role for HER2 in colorectal cancer than in breast or stomach cancer. In the trial that led to the first colorectal approval, NGS-detected amplification in tumor tissue was one of the accepted ways to qualify. NGS can also be done on a blood sample, called a liquid biopsy. Your care team will decide whether to confirm a blood result on tissue.

How results are reported

HER2 results in colorectal cancer may appear in the pathology report, a separate molecular report, or both. Common results include:

  • HER2-negative (IHC 0 or 1+). The cancer produces little HER2 protein.
  • HER2 equivocal (IHC 2+). The result is borderline. ISH or NGS is needed to check for amplification, and the report may say this testing has been ordered.
  • HER2-positive (IHC 3+, or IHC 2+ with amplified ISH). The cancer makes too much HER2 or has extra copies of the gene. The report may name the scoring rules used.
  • HER2 (ERBB2) amplification by NGS. The molecular report says the gene has extra copies, sometimes with a copy number. This result often counts as HER2-positive in colorectal cancer.
  • HER2 (ERBB2) mutation by NGS. The test found a change in the gene itself, not extra copies. This is not the same as HER2-positive disease.

What the result means

HER2-negative

A HER2-negative colorectal cancer is not expected to respond to HER2-targeted drugs. This is the most common result. Treatment is then guided by the RAS, BRAF, and mismatch repair (MMR) results and the cancer stage.

HER2 equivocal (IHC 2+)

An equivocal HER2 result in colorectal cancer means the staining is borderline. ISH or NGS then decides whether the gene is amplified. If it is, the cancer is HER2-positive. If it is not, the cancer is HER2-negative.

HER2-positive

A HER2-positive colorectal cancer is driven partly by too much HER2, and HER2-targeted drugs may help. These cancers are usually RAS- and BRAF-wildtype. That would normally make anti-EGFR drugs an option, but HER2 amplification can make those drugs less effective. Your oncologist will weigh this when planning treatment.

HER2 mutation

HER2 mutations are found in about 4% of colorectal cancers. They are studied in clinical trials, including trials of HER2-targeted drugs. The approved colorectal treatments described in this article are for HER2-positive cancer, not for HER2 mutations. Your oncologist can tell you whether a trial might be an option.

Treatments linked to HER2-positive results

The FDA approves HER2-targeted drugs for colorectal cancer for cancer that cannot be removed with surgery or has spread, after earlier treatment. Approvals in other countries may differ. Your oncology team weighs each option alongside your RAS result, earlier treatment, and overall health.

  • Tucatinib (Tukysa) with trastuzumab (Herceptin). Trastuzumab is an antibody that blocks HER2 from the outside of the cell. Tucatinib is a pill that blocks HER2 from inside the cell. The FDA approved this combination in January 2023 for RAS wild-type, HER2-positive colorectal cancer that grew after standard chemotherapy. It was the first HER2-targeted treatment approved for colorectal cancer. In the trial, the cancer shrank in about 38% of patients, and responses lasted a median of about one year.
  • Trastuzumab deruxtecan (Enhertu). This drug links a HER2 antibody to a chemotherapy drug, delivering the chemotherapy directly to HER2-positive cells. The FDA approved it in April 2024 for any solid tumor with an IHC score of 3+, including colorectal cancer, after earlier treatment. In colorectal cancers with an IHC score of 3+, the cancer shrank in about 47% of patients. This approval requires an IHC 3+ score and does not require the cancer to be RAS wild-type.

A large trial called MOUNTAINEER-03 is testing whether tucatinib and trastuzumab work better when added to the first chemotherapy given for metastatic disease. Ask your oncologist whether you might qualify for this or other HER2 trials.

HER2 and anti-EGFR treatment

HER2 amplification matters for anti-EGFR treatment in colorectal cancer because it gives the cancer a second route for growth signals. Cetuximab and panitumumab block EGFR, but not HER2. A HER2-amplified cancer can keep growing through HER2 even while EGFR is blocked. This is why a cancer that is RAS and BRAF wild-type may still respond poorly to anti-EGFR drugs. For this reason, many oncologists check HER2 status before choosing anti-EGFR treatment.

Does HER2 status have hereditary implications?

HER2 changes in colorectal cancer develop within the cancer cells and are not inherited. A HER2 result does not show an inherited cancer risk for family members. Inherited risk for colorectal cancer is assessed in other ways, mainly through MMR testing for Lynch syndrome.

What happens next

What happens after HER2 testing in colorectal cancer depends on the final result:

  • If HER2-negative. HER2-targeted drugs are not part of the plan based on this result. Your other biomarker results and the cancer stage guide treatment.
  • If equivocal (IHC 2+). ISH or NGS is performed, and your care team explains the next steps once the final result is available.
  • If HER2-positive. Your oncologist will discuss whether tucatinib with trastuzumab or trastuzumab deruxtecan may be options, now or later. They may also discuss how the result affects anti-EGFR treatment and whether a clinical trial is suitable.
  • Suppose a HER2 mutation was found. Your oncologist will explain what the specific mutation means and whether a clinical trial may be available.

HER2 status can differ between the original tumor and areas of spread, or change over time. If the cancer grows or a new biopsy is taken, HER2 may be tested again, especially if an earlier result was borderline.

Questions to ask your doctor

  • Was my colorectal cancer tested for HER2, and what was the result?
  • Which test was used: IHC, ISH, NGS, or a blood test?
  • Which scoring rules did the laboratory use for my IHC result?
  • If my result was 2+, has ISH or NGS been done to check for amplification?
  • Did NGS find a HER2 amplification or a HER2 mutation?
  • Are my KRAS, NRAS, and BRAF results wild-type?
  • Does my HER2 result affect whether anti-EGFR treatment is a good option for me?
  • If my cancer is HER2-positive, am I a candidate for tucatinib with trastuzumab or trastuzumab deruxtecan?
  • Are these treatments approved and available where I live?
  • Could HER2 explain why my cancer stopped responding to cetuximab or panitumumab?
  • Should my HER2 status be retested if the cancer grows?
  • Are there clinical trials of HER2-targeted treatment that I might qualify for?

Related articles on MyPathologyReport.com

A+ A A-
Was this article helpful?